Observational Study
researchers track health outcomes over time in groups of participants to look for patterns that help us better understand a disease.
CureGN
Cure Glomerulonephropathy Network
Cure Glomerulonephropathy (CureGN) is a multicenter five-year observational study of glomerular disease patients.
Trial Physician / Study Coordinator
Caroline Poulton
Email Phone 919-445-2636Site Name
University of North Carolina Kidney Center
7024 Burnett-Womack Building
Observational Study
researchers track health outcomes over time in groups of participants to look for patterns that help us better understand a disease.
CureGN
Cure Glomerulonephropathy Network
Cure Glomerulonephropathy (CureGN) is a multicenter five-year observational study of glomerular disease patients.
Eligibility Criteria
Patient Population
Primary focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), membranous nephropathy (MN), and IgA nephropathy (IgAN)
Age
0 — 26+
History of transplant allowed?
Yes, No
History of dialysis allowed?
Yes, No
eGFR
15 — > 60
UPCR
1.0 or Less — 3.0 or Above
Permitted medication history
Ace Inhibitors/ARB, Prednisone (Steroids), Abatacept, Acthar, Cellcept (AKA Mycophenolate), Cytoxan (Cyclophosphamide), Prograf (AKA Tacrolimus), Rituximab (AKA Rituxan), Other, None
Patient should be
Treatment Resistant, Steroid Dependent, Neither of These
About the Drug
What is involved for the patient
Participants’ health will be monitored over 5 years. This may require extra visits to your doctor.
Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
About the Trial
Study Goal
The CureGN project will study 2,400 children and adults with the following glomerular diseases: minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), and IgA nephropathy (IgAN).